Early morning Beijing time on June 3, longevity biotech startup NewLimit announced the completion of a $435 million Series C funding round. The round was led by Peter Thiel's Founders Fund, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, and new backers including Thrive Capital, Greenoaks, and Quiet Capital.
The Wall Street Journal reported that the new funding values NewLimit at $3.1 billion, more than tripling its valuation from a year ago. In the funding announcement, the company revealed that following breakthrough research results, it is now moving longevity medicine into human clinical trials. Its first drug candidate, targeting alcohol-related liver disease, is expected to enter clinical trials next year.
From Crypto Exchange to Cellular Reprogramming
NewLimit was co-founded by none other than Brian Armstrong, the founder and CEO of cryptocurrency exchange Coinbase. In 2021, Armstrong teamed up with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel to start the company in South San Francisco with an initial $110 million commitment.
Prior to the Series C, NewLimit had already completed three rounds of financing. According to its official description, the company is dedicated to developing medicines that extend human healthspan: “As we age, our cells progressively decline in function, increasing our vulnerability to disease. It was once thought that aging was inevitable, but emerging science shows that the aging process can be reversed at the cellular level. We are building on these discoveries to create the first drugs that restore youthful function to aged cells.”
In simple terms, NewLimit is using rigorous science to tackle the prospect of significantly delaying, or perhaps even reversing, biological aging.
Yamanaka Factors: The Scientific Foundation
For decades, science acknowledged the link between aging and cellular decline but could not pinpoint a method to rejuvenate cells. The breakthrough came in 2006, when Japanese scientist Shinya Yamanaka discovered that activating just a handful of specific transcription factors could reprogram adult cells back into a youthful embryonic-like state. This discovery, later named Yamanaka Factors, earned him the 2012 Nobel Prize in Physiology or Medicine.
Yamanaka’s work proved for the first time that cellular age is not irreversible, and NewLimit’s entire thesis rests on this foundation. The company’s website states: “Our medicines work by activating specific transcription factor genes to reprogram the epigenome of cells to a younger state. We already know this reversal is possible. But for different cell types, the exact combination of transcription factors needed to restore youthful function remains unknown. Finding and discovering these effective payloads is the core challenge of our work.”
Starting with Liver Disease, Heading to the Clinic
NewLimit’s strategy is to first tackle a specific disease, secure regulatory approval, and then expand to broader applications. The company has chosen alcohol-related liver disease as the initial indication, with the first clinical trial set to begin next year.
Co-founder and CEO Jacob Kimmel further explains that liver disease can be viewed as an “accelerated aging” process—simply manifesting the universal aging trajectory in a faster and more dramatic way. This framing could shorten the path from lab to market.
Tech Billionaires’ Race Against Time
NewLimit is far from alone in the longevity space. In 2022, Sam Altman invested $180 million into Retro Biosciences, which is developing rejuvenation therapies for aged cells and was recently reported to be valued at $1.8 billion. Meanwhile, Altos Labs, reportedly backed by Jeff Bezos, launched in 2022 with $3 billion in funding and has since seen its total capital nearly double.
From Peter Thiel to Sam Altman to Jeff Bezos, those betting heavily on longevity consistently sit at the very top of the tech and wealth pyramid. Thiel has famously expressed his disdain for death, calling it humanity’s greatest enemy. The logic is straightforward: when wealth and power reach their apex, time becomes the only enemy—and the last luxury that money alone cannot buy.